Holen Sie sich die Stockscreener-App
3.98
3.11%
0.12
Handel nachbörslich:
3.98
Schlusskurs vom Vortag:
$3.86
Offen:
$3.84
24-Stunden-Volumen:
728.12K
Relative Volume:
0.72
Marktkapitalisierung:
$347.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-7.1071
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
-3.40%
1M Leistung:
-1.24%
6M Leistung:
-26.70%
1J Leistung:
+123.60%
1-Tages-Spanne:
$3.7801
$4.09
1-Wochen-Bereich:
$3.71
$4.245
52-Wochen-Spanne:
$1.75
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
3.98 | 347.02M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha
Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq
Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener
Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia
Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com
Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus
Spotlight On Top Penny Stocks For May 2025 - simplywall.st
Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus
Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable
Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals shares surge on positive trial results - Investing.com
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo
Corvus: Q1 Earnings Snapshot - New Haven Register
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com
Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha
Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India
Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corvus Pharmaceuticals Inc-Aktie (CRVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):